Potential of DNA Patterns in Predicting Blood Cancer Progression

Recent research suggests that DNA patterns might identify the progression of certain blood cancers years before routine tests can detect changes. Published in the journal Cancer Discovery, the study involved 30 individuals with myeloproliferative neoplasms (MPNs), a group of blood cancers characterized by excessive blood cell production in the bone marrow.

Research Findings on MPNs

Researchers from the Wellcome Trust Sanger Institute in the U.K. tracked genetic changes in the DNA from the patients’ blood and bone marrow. They investigated whether these changes had links to blood counts, stable disease, or progression to more severe conditions like myelofibrosis or acute leukemia.

“Stable disease often correlates with stable DNA lacking cancer-related changes, suggesting a genetically stable MPN remains likely to stay stable,” according to the researchers.

The study found that patients whose disease worsened exhibited DNA changes years prior to any signs noticed in routine blood tests. Abnormal cell groups emerged and expanded during this period.

Different Disease Progression Paths

Nine participants developed acute myeloid leukemia (AML), revealing diverse progression patterns. In some, MPN cells accumulated harmful mutations gradually. Others developed leukemia from separate abnormal blood cells. Similar variations appeared in those developing myelofibrosis.

Researchers also identified that hydroxyurea, a medicine used for controlling blood counts in MPN patients, induces recognizable DNA changes. Yet, there was no indication that it leads to leukemia. A similar DNA pattern emerged with azacitidine, a drug for treating certain blood cancers.

Interestingly, three patients with “triple-negative” essential thrombocythemia showed no genetic cancer signs, indicating some individuals labeled with this condition may not require long-term cancer treatment.

The Role of DNA Monitoring

An expert not involved in the study, Dr. Abhishek Chilkulwar, an oncologist at Orlando Health, emphasized the long life span potential for MPN patients. The research demonstrates that DNA markers might predict cancer development a decade ahead of time. This paves the way for precision medicine, potentially allowing patients to manage their disease preemptively rather than reactively.

“This research indicates future blood cancer courses could be detectable in DNA long before clinical symptoms emerge,” he noted.

While the study doesn’t advocate immediate changes in treatment, it suggests more frequent genetic testing. This could alert healthcare providers early about possible disease progression, ahead of routine tests.

Dr. Chilkulwar explained that the next step would be integrating early genetic detection with drugs targeting specific mutations, aiming to prevent or delay disease progression. However, until new treatments are developed, more frequent monitoring remains the practical application.

Advanced monitoring could involve frequent blood and bone marrow evaluations for patients with high-risk mutations to catch early progression signs. In contrast, procedures like stem cell transplants should remain for patients who progress to more severe stages of MPN.